Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q4 2019 · 10-K
Revenue$11.77M$11.77M−71.1% vs Q4 2018 Net Income-$26.46M-$26.46MN/M vs Q4 2018 EPS Diluted-$0.72-$0.72N/M vs Q4 2018 Operating Incomederived-$40,324,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
Operating Cash Flowderived-$25,506,000N/M Free Cash Flowderived-$26,537,000N/M Margins · derivedOperating margin-342.7%−348.7 pt vs Q4 2018
Net margin-224.9%−235.4 pt vs Q4 2018
ended Dec 31, 2019 · filed Feb 26, 2020 · 57 d after period end